Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.
The Institute for Clinical and Economic Review's ambitious review agenda for 2018 includes cutting edge and likely extremely expensive therapies targeting relatively small patient populations, as well as drugs with novel mechanisms that are poised to shake up categories covering broad numbers of patients.
ICER's tentative agenda, released July 26, is drawn from the organization's horizon scans of new and emerging therapies, conversations with...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
